Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Single Arm, Dose Escalation and Cohort Expansion Study to Evaluate Safety, Preliminary Efficacy of HL-085 in Patients With NRAS Mutant Advanced Melanoma

NCT03973151 is registered in ClinicalTrials.gov with Shanghai Kechow Pharma, Inc. as lead sponsor.

NCT NCT03973151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03973151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Single Arm, Dose Escalation and Cohort Expansion Study to Evaluate Safety, Preliminary Efficacy of HL-085 in Patients With NRAS Mutant Advanced Melanoma
Lead sponsor
Shanghai Kechow Pharma, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 1, 2017
Completion date
January 18, 2021
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma